Soleno Therapeutics Announces November Conference Participation
Soleno Therapeutics Ready for November Investor Conferences
Soleno Therapeutics, Inc. (NASDAQ: SLNO), a pioneering biopharmaceutical firm, is excited to announce its participation in several important investor conferences this coming November. Located in Redwood City, California, Soleno specializes in developing innovative medicines aimed at treating rare diseases.
Highlighting Upcoming Conferences
The company is set to make significant appearances at the following conferences:
Guggenheim Securities Healthcare Innovation Conference
Date of Presentation: November 11
Time: 9:00 AM ET
Format: Fireside Chat
This conference is renowned for its focus on healthcare innovation and presents an opportunity for Soleno to engage with industry leaders and investors.
Stifel 2025 Healthcare Conference
Date of Presentation: November 12
Time: 8:40 AM ET
Format: Fireside Chat
This gathering is another pivotal event where Soleno plans to share insights about its ongoing projects and future plans.
Jefferies London Healthcare Conference
Date of Presentation: November 18
Time: 5:00 PM GMT
Format: Presentation
Soleno is looking forward to international exposure at this notable conference, emphasizing its commitment to expanding its footprint in the rare disease therapeutic space.
Access to Conference Replays
For those unable to attend live, replays of these valuable discussions will be available in the Investors section on the Company's website at www.soleno.life.
About Soleno Therapeutics, Inc.
Soleno is dedicated to the development of novel therapeutics designed specifically for managing rare diseases. Its flagship product, VYKAT XR™ (diazoxide choline) extended-release tablets, is an innovative once-daily oral treatment option aimed at alleviating hyperphagia in individuals aged four and above with Prader-Willi syndrome. This product marks a significant milestone in the company's exciting journey in the biopharmaceutical industry.
Corporate Contact
For further inquiries, please contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
Frequently Asked Questions
What is Soleno Therapeutics focusing on?
Soleno Therapeutics focuses on developing treatments for rare diseases, with a particular emphasis on innovative therapeutic solutions.
What is VYKAT XR™?
VYKAT XR™ is a once-daily oral treatment for hyperphagia in patients with Prader-Willi syndrome, facilitating better management of this rare disorder.
When can investors expect to hear from Soleno at these conferences?
Soleno's presentations are scheduled across multiple dates in November, providing a platform for engaging discussions about their advancements and plans.
Where can I find replay information for the conferences?
Replays will be accessible in the Investors section of Soleno's official website after the live events.
How can I contact Soleno Therapeutics?
For inquiries, you can reach Brian Ritchie at LifeSci Advisors, LLC at the phone number provided above.
About The Author
Contact Dominic Sanders privately here. Or send an email with ATTN: Dominic Sanders as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
